Business context and reporting period
Stryker Corporation’s Form 8-K, dated October 6, 2026, reports a planned CEO succession and related compensation and Board changes. It does not report quarterly or annual operating results.
Key financial and compensation information
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating performance metrics.
- Effective January 1, 2027, Spencer S. Stiles’s annual base salary will be $1,320,000 and his annual bonus target will be 150% of base salary. Benefit-plan eligibility is unchanged.
- A recommendation is expected for independent directors to approve a February 2027 long-term incentive award for Mr. Stiles with a target grant-date fair value of $14,200,000: 40% stock options and 60% performance stock units (PSUs). The award is not stated as approved; PSU shares depend on performance goals.
- Kevin A. Lobo’s base salary, bonus target, and benefit-plan eligibility will remain unchanged as Executive Chair. He will not be eligible for new stock awards in that role.
Material changes and management commentary
- Mr. Lobo will remain CEO through December 31, 2026, then become Executive Chair on January 1, 2027.
- Mr. Stiles, currently President and COO, will become CEO on January 1, 2027. He has worked at Stryker for 27 years and held leadership roles across Orthopaedics, MedSurg, Neurotechnology, and international regions.
- The Board increased from 10 to 11 members and appointed Mr. Stiles as a director, effective January 1, 2027. He has not been assigned to a Board committee.
Outlook, risks, contingencies, and unusual items
This filing announces leadership changes and does not provide business guidance or an operating outlook. The proposed incentive award remains subject to independent director approval and the applicable plan terms; PSU vesting is tied to performance goals. The filing reports no other specific risks or contingencies.
Important facts to verify
- Confirm the CEO and Executive Chair transitions take effect as scheduled on January 1, 2027.
- Check whether independent directors approve the proposed $14.2 million target-value award and review its final terms.
- Review subsequent filings for any changes to compensation, Board composition, or leadership arrangements.